89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

The company’s lead product candidate, pegozafermin (BIO89-100), is an investigational glycopegylated FGF21 analog currently being evaluated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

The company believes that targeting FGF21, a metabolic hormone that regulates energy expenditure and glucose and lipid metabolism, may be a promising option for people with liver and cardiometabolic diseases, such as MASH and SHTG.